Using quantitative immunoprecipitation mass spectrometry (QIP-MS) to identify low level monoclonal proteins

Campbell, Lauren; Simpson, Dawn; Ramasamy, Karthik; Sadler, Ross

doi:10.1016/j.clinbiochem.2021.05.012

Cited by 7 publications

(3 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Besides these two approaches, the first results of a third MS version termed 'quantitative immunoprecipitation mass spectrometry' (QIP-MS) have been recently presented [170]. This assay enables the identification, quantification, and typing of complete and LC-only M-proteins at once.…”

Section: Mass Spectrometrymentioning

confidence: 99%

Minimal Residual Disease in Multiple Myeloma: Past, Present, and Future

Medina-Herrera

Sarasquete

Jiménez

et al. 2023

Cancers

View full text Add to dashboard Cite

Responses to treatment have improved over the last decades for patients with multiple myeloma. This is a consequence of the introduction of new drugs that have been successfully combined in different clinical contexts: newly diagnosed, transplant-eligible or ineligible patients, as well as in the relapsed/refractory setting. However, a great proportion of patients continue to relapse, even those achieving complete response, which underlines the need for updated response criteria. In 2014, the international myeloma working group established new levels of response, prompting the evaluation of minimal residual disease (MRD) for those patients already in complete or stringent complete response as defined by conventional serological assessments: the absence of tumor plasma cells in 100,000 total cells or more define molecular and immunophenotypic responses by next-generation sequencing and flow cytometry, respectively. In this review, we describe all the potential methods that may be used for MRD detection based on the evidence found in the literature, paying special attention to their advantages and pitfalls from a critical perspective.

show abstract

Section: Mass Spectrometrymentioning

confidence: 99%

Minimal Residual Disease in Multiple Myeloma: Past, Present, and Future

Medina-Herrera

Sarasquete

Jiménez

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…During the IP, target proteins or peptides at low concentrations are enriched using antibodies (see Figure 4). Then MS allows an accurate analysis of levels of these proteins or peptides (Uljon et al, 2000;Campbell et al, 2021). Richard et al (2019) proposed a simplified ad detailed protocol for robust immunoprecipitation of Aβ before mass spectrometric detection.…”

Section: Immunoprecipitation-mass Spectrometrymentioning

confidence: 99%

Is liquid biopsy mature enough for the diagnosis of Alzheimer’s disease?

Gong

Zhang

Liu

et al. 2022

Front. Aging Neurosci.

View full text Add to dashboard Cite

The preclinical diagnosis and clinical practice for Alzheimer’s disease (AD) based on liquid biopsy have made great progress in recent years. As liquid biopsy is a fast, low-cost, and easy way to get the phase of AD, continual efforts from intense multidisciplinary studies have been made to move the research tools to routine clinical diagnostics. On one hand, technological breakthroughs have brought new detection methods to the outputs of liquid biopsy to stratify AD cases, resulting in higher accuracy and efficiency of diagnosis. On the other hand, diversiform biofluid biomarkers derived from cerebrospinal fluid (CSF), blood, urine, Saliva, and exosome were screened out and biologically verified. As a result, more detailed knowledge about the molecular pathogenesis of AD was discovered and elucidated. However, to date, how to weigh the reports derived from liquid biopsy for preclinical AD diagnosis is an ongoing question. In this review, we briefly introduce liquid biopsy and the role it plays in research and clinical practice. Then, we summarize the established fluid-based assays of the current state for AD diagnostic such as ELISA, single-molecule array (Simoa), Immunoprecipitation–Mass Spectrometry (IP–MS), liquid chromatography–MS, immunomagnetic reduction (IMR), multimer detection system (MDS). In addition, we give an updated list of fluid biomarkers in the AD research field. Lastly, the current outstanding challenges and the feasibility to use a stand-alone biomarker in the joint diagnostic strategy are discussed.

show abstract

“…The minimally invasive technology mass spectrometry (MS), which is amenable to automation, is emerging as a promising approach for detecting and monitoring monoclonal proteins in the peripheral blood (PB) [5][6][7][8][9]. MS has been shown to be superior to standard electrophoretic methods for the detection of monoclonal immunoglobulins, such as serum immunofixation (IFE) [10][11][12][13]. Furthermore, recent data suggests a role for MS as a complementary approach for the detection of minimal residual disease (MRD) [11,13], overcoming the limitations of bone marrow-based methods for identifying systemic disease.…”

Section: Introductionmentioning

confidence: 99%

Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma

et al. 2023

View full text Add to dashboard Cite

Mass spectrometry (MS) is a promising tool for monitoring monoclonal protein in plasma cell dyscrasias. We included 480 transplant-eligible newly-diagnosed multiple myeloma (MM) patients from the GMMG-MM5 trial (EudraCT No. 2010-019173-16) and performed a retrospective MS analysis at baseline (480 patients) and at the pre-defined, consecutive time points after induction (444 patients), prior to maintenance (305 patients) and after one year of maintenance (227 patients). We found that MS negativity was significantly associated with improved progression-free survival (PFS) even in patients with complete response (CR) at all investigated follow-up time points. The prognostic impact was independent of established risk factors, such as the revised International Staging System. Combining MS and baseline cytogenetics improved the prediction of outcome: MS-positive patients with high-risk cytogenetics had a dismal PFS of 1.9 years (95% confidence interval [CI]: 1.6–2.3 years) from the start of maintenance. Testing the value of sequential MS prior to and after one year of maintenance, patients converting from MS positivity to negativity had an excellent PFS (median not reached) while patients converting from MS negativity to positivity progressed early (median 0.6 years, 95% CI: 0.3-not reached). Among patients with sustained MS positivity, the baseline high-risk cytogenetic status had a significant impact and defined a group with poor PFS. Combining minimal residual disease (MRD) in the bone marrow and MS allowed the identification of double negative patients with a favorable PFS (median 3.33 years, 95% CI: 3.08-not reached) and no overall survival events. Our study provides strong evidence that MS is superior to conventional response monitoring, highlighting the potential of MS to become a new standard. Our data indicate that MS should be performed sequentially and combined with baseline disease features and MRD to improve its clinical value.Clinical Trials Register: EudraCT No. 2010-019173-16

show abstract

Using quantitative immunoprecipitation mass spectrometry (QIP-MS) to identify low level monoclonal proteins

Cited by 7 publications

References 12 publications

Minimal Residual Disease in Multiple Myeloma: Past, Present, and Future

Minimal Residual Disease in Multiple Myeloma: Past, Present, and Future

Is liquid biopsy mature enough for the diagnosis of Alzheimer’s disease?

Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma

Contact Info

Product

Resources

About